Jubilant Pharmova Ltd reported a consolidated net profit of ₹1.2 billion for Q2 FY2026, with total revenue from operations reaching ₹19.66 billion. The growth was driven by strong performance in contract manufacturing, specialty pharmaceuticals, and cost optimization across global operations.
                                        
                        
	Jubilant Pharmova Ltd reported a consolidated net profit of ₹1.2 billion for Q2 FY2026, with total revenue from operations reaching ₹19.66 billion. The growth was driven by strong performance in contract manufacturing, specialty pharmaceuticals, and cost optimization across global operations.
	 
	Main Story: Jubilant Pharmova Ltd has announced its Q2 FY2026 financial results, showcasing a resilient performance across its diversified pharmaceutical segments. The company posted a consolidated revenue of ₹19.66 billion, supported by robust demand in contract development and manufacturing (CDMO) and radiopharma businesses.
	 
	Net profit rose to ₹1.2 billion, reflecting a healthy year-on-year growth. The company attributed this to operational efficiencies, strategic cost control, and steady export momentum. Jubilant’s US-based subsidiary also prepaid a USD 25 million term loan, strengthening its balance sheet and reducing interest costs.
	 
	Management highlighted continued investments in R&D, digital transformation, and global expansion, particularly in sterile injectables and allergy immunotherapy. The company remains optimistic about sustained growth in H2 FY2026, backed by a strong order pipeline and regulatory approvals.
	 
	Key Highlights:
	- 
		Revenue from Operations: ₹19.66 billion
- 
		Net Profit: ₹1.2 billion
- 
		Growth Drivers: CDMO, radiopharma, cost optimization
- 
		Strategic Moves: USD 25 million loan prepayment by US subsidiary
- 
		Outlook: Positive on exports, specialty pharma, and global expansion
	Jubilant Pharmova’s Q2 results reflect its strategic agility and operational strength in a competitive global pharma landscape.
	 
	Sources: Jubilant Pharmova Investor Relations, 5paisa, LiveMint